MARKET

MEIP

MEIP

Mei Pharma Inc
NASDAQ
3.150
+0.220
+7.51%
Closed 16:00 05/17 EDT
OPEN
2.960
PREV CLOSE
2.930
HIGH
3.180
LOW
2.960
VOLUME
13.28K
TURNOVER
0
52 WEEK HIGH
6.91
52 WEEK LOW
2.870
MARKET CAP
20.99M
P/E (TTM)
0.8025
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)
TipRanks · 5d ago
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
Glancy Prongay & Murray LLP announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws. This press release may be considered Attorney Advertising in some jurisdictions.
Barchart · 05/14 09:38
Weekly Report: what happened at MEIP last week (0506-0510)?
Weekly Report · 05/13 09:52
MEI Pharma, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 19:26
MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
MEI Pharma reported earnings per share of -$1.37 for the third quarter of 2024. The company did not report any revenue for the quarter. MEI Pharma's quarterly results were above the analyst estimate for -$0.52 per share. MEi Pharma is a pharmaceutical company.
Investorplace · 05/10 02:57
MEI Pharma Inc reports results for the quarter ended in March - Earnings Summary
MEI Pharma Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of $1.37 per share. MEI Pharma shares have fallen by 21.0% this quarter and 45.5% so far this year. Wall Street's median 12-month price target for the company is $20.00.
Reuters · 05/09 21:54
MEI Pharma GAAP EPS of -$1.37 beats by $0.12
Seeking Alpha · 05/09 21:28
More
About MEIP
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).

Webull offers MEI Pharma Inc stock information, including NASDAQ: MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.